The bioorganic synthesis of an end-capped anti-HIV peptide from a recombinant protein was investigated. Cyanogen bromide-mediated cleavage of two Met-Gln sites across the target anti-HIV sequence generated an HIV-1 fusion inhibitor (SC35EK) analog bearing an N-terminal pyroglutamate (pGlu) residue and a C-terminal homoserine lactone (Hsl) residue.
N-terminal protecting group as this residue is important for the physiological stability of several mammalian peptide hormones and proteins. 16 The cyclic structure of pGlu can be obtained by cyclization from a glutamine (Gln) residue mediated either by glutaminyl cyclase in vivo, or by treatment of Gln in non-enzymatic conditions. 16, 17 In this study, we undertook the bioorganic synthesis of an SC35EK analog, which contains cyclic N-terminal pGlu and C-terminal Hsl end-capping structures. 18 Using a model synthetic peptide, the conditions necessary for the cleavage and cyclization of a Gln residue to a pGlu residue were optimized. Recombinant His-tag fusion proteins containing either a single, or three consecutive anti-HIV sequences were expressed and purified from E. coli. The peptide, pGlu-SC35EK-Hsl, was cleaved from the resulting recombinant protein under optimized acidic conditions. We then assessed the biological and biophysical characteristics of pGlu-SC35EK-Hsl and its biostability in mouse serum.
Results and discussion

Cleavage and cyclization of the model synthetic peptide
In order to obtain the end-capped SC35EK protein, we incorporated two Met-Gln dipeptide cleavage sites across the anti-HIV SC35EK sequence. A CNBr-mediated cleavage should provide a C-terminal Hsl residue and an N-terminal Gln residue, which could then be converted into pGlu under mildly acidic conditions. Using a model synthetic peptide Ac-MQ-WEEWDKK-MQ-OH (MQ-SC7EK-MQ) 1 derived from the N-terminal sequence of SC35EK, the acidic conditions for CNBr-mediated cleavage and cyclization were optimized (Scheme 1). The reaction products were analyzed using LC-MS and the yields of Gln-SC7EK-Hsl 2 and pGlu-SC7EK-Hsl 3 were calculated based upon the peak areas at 220 nm ( Table 1 ). The pGlu formation was verified by the comparative analysis with the authentic sample obtained by chemical synthesis using pyroglutamic acid. CNBr-mediated cleavage of peptide 1 in the standard 70% formic acid (FA) solution yielded Gln-SC7EK-Hsl 2 without the oxidation of Met residues (entry 1). Significant Met oxidation, which disrupted the cleavage reaction, was observed under the other acidic conditions, including 30% FA, 0.1 N HCl, 0.1 M trifluoroacetic acid (TFA) and 0.1 N AcOH. This by-product formation was prevented by the addition of tris(2-carboxyethyl)phosphine (TCEP) (entries 2-5). Partial production of the expected pGlu derivative 3 was observed in all cases in which this cyanylation step was carried out. The second cyclization, from N-terminal Gln to pGlu, was completed within 2 h. However, when 0.1 N AcOH solution was used, the reaction was incomplete ( Fig. 1 ). Small amounts of formylated by-product were obtained along with peptide 3 in 70% FA solution, but peptide 3 was produced in higher yield (entry 1).
Preparation of recombinant His-tagged fusion protein
We used the pET28a(+) vector to express a hexa-histidine tagged [His-tag, The (His) 6 -MQ-SC35EK-MQ protein 4 was highly expressed in the soluble fraction and was obtained by elution with either imidazole or above acidic solutions from the affinity chromatography resin ( Fig. 2a ). Using the standard imidazole protocol, protein 4 was eluted in a moderate yield, however, approximately 100 mg of 4 was recovered from 1 L of bacterial culture under acidic solutions ( Table 2 ). The lower yield obtained after elution using imidazole may be attributable either to incomplete protein elution from the column and/or protein loss during the desalting process. The purity of the (His) 6 -MQ-SC35EK-MQ 4 was confirmed as >95% by HPLC ( Fig. 4a ). (His) 6 -M-(Q-SC35EK-M) 3 -Q 5 was expressed in both the soluble and insoluble fractions ( Fig. 2b) and this resulted in a decreased yield, regardless of the high expression level seen in the total fraction. Consequently, only 19 or 26 mg/L of protein 5 was obtained by elution with imidazole or acidic solutions, respectively, (including 70% FA, 0.1 N HCl, or 0.1 M TFA), with <80% purity confirmed by HPLC. Thus, (His) 6 -MQ-SC35EK-MQ 4 was used for the further experiments.
Production of the anti-HIV peptide by cleavage and cyclization of the recombinant protein
The optimized cleavage protocol established above was applied to (His) 6 -MQ-SC35EK-MQ 4. Purified protein 4 was cleaved and cyclized simultaneously by CNBr treatment under acidic conditions at 60 ºC for 2 h (Scheme 2, and Fig. 3 ). All the LC-MS profiles indicated the formation of two major products corresponding to the tag fragment 6 and pGlu-SC35EK-Hsl 7 (Fig. 4b, top) . The formylated by-products of 6 and 7 were only obtained by reaction in 70% FA. This result agrees with that obtained using the model peptide, and also with previous reports. 15b Significant amounts of ring-opened products at the C-terminal Hsl of 6 and 7 were observed when the cleavage reaction was carried out in either 0.1 N HCl or 0.1 M TFA (Fig. 4b, middle and bottom) . pGlu-SC35EK-Hsl 7 obtained under all conditions was purified by HPLC with >99% purity (Fig. 4c ). Peptide 7 was characterized by ESI-MS measurement and by the comparative analysis with the one obtained by chemical synthesis using pGlu (see Supplementary data). The cyclization yields of 
Cleavage and cyclization of the model peptide
The model synthetic peptide MQ-SC7EK-MQ 1 was treated with CNBr (100 equiv) in the presence of TCEP (10 equiv) under acidic conditions at room temperature for 2 h. After cleavage at the Met residue, the reaction mixture was heated at 60 °C for 2 h. The reaction products were analyzed every 30 min using LC-MS (Fig. 1) . The Gln-SC7EK-Hsl 2 or the pGlu-SC7EK-Hsl 3 peptides were quantified based on the combined peak areas at 220 nm of peptides after HPLC.
Preparation of recombinant (His) 6 -fused proteins.
The cDNA sequences encoding the MQ-SC35EK-MQ or M-(Q-SC35EK-M) 3 
Stability of SC35EK peptide or analogs in mouse serum.
presence of 0.1% m-cresol (internal standard). 0.010 mL samples were collected at 0, 0.5, 1, 3, 6, 9 and 12 h and the reaction was terminated by the addition of 1 µL 0.1 N HCl and 0.040 mL of CH 3 CN. Samples were deproteinized by centrifugation at 12,000 rpm for 10 min and 0.010 mL of the supernatant was injected into LC-MS. The percentage of intact peptides was calculated by peak area and corrected against the internal standard. Cyclization of Gln to pGlu by heating the reaction at 60 ºC under acidic conditions was monitored every 30 min for 2 h. The yields were calculated based on the combined peak areas at 220 nm of HPLC. 
